Double cord blood transplantation (CBT) with ex-vivo expansion aims at overcoming the delayed engraftment frequently observed after CBT. Thirty-one patients received myeloablative therapy with melphalan, fludarabine, thiotepa and ATG followed by double CBT for treatment of hematologic malignancies. One of the 2 units was expanded (exp) ex-vivo in a co-culture with either third party haploidentical family member marrow derived mesecnchyal stem cells (N 5 8) or off-the-shelf mesenchymal progenitor cells from Angioblast (N 5 23). Both CB units were matched in at least 4/6 HLA antigens with the patient, and contained a minimum of 1x10 7 TNC/ Kg per unit. The majority of patients (pts) received CBT for treatment of acute leukemia including AML / MDS (64%) and ALL (19%), and 42% were in remission at CBT. Median age was 36 years (range 2.8-62). The non-exp unit was matched with the pt in 6/6 HLA antigens in 3%, 5/6 in 26% and 4/6 in 71% of cases; the corresponding distribution for the exp unit was 6%, 29%, 64%. Engraftment was documented in 29 evaluable pts at a median of 15 (range 9 to 42) days for neutrophils and 40 (range 18 to 62) days for platelets. Day 30 chimerism showed evidence of engraftment of the non-exp unit only in 15 (52%) pts, and of both units in 13 (45%) pts, including 9 and 4 in whom the non-exp and the exp unit dominated, respectively. Chimerism was undetermined in 1 pt. Comparison of the rate of recovery in pts who had (N 5 13) and those who did not have (N 5 15) evidence of engraftment of the exp unit showed that neutrophils and platelet recovery was faster when the exp unit engrafted (median of 15 vs. 19 days for neutrophils; and 38 vs. 40 days for platelet). This difference did not reach statistical significance however. The median numbers of TNC and CD34+ cells infused/Kg were significantly higher in the engrafted exp than in the non-engrafted exp unit (p \ 0.05). Sixteen pts were diagnosed with grade II-IV aGVHD including 12 within 100 days post CBT. GVHD was severe (grade III-IV) in 5 pts. On univariate analysis, there was a trend for a higher 6 month rate of grade II-IV aGVHD when the exp unit engrafted (cumulative incidence (CI) 65% vs 49%, P 5 0.2); when the non-exp unit was only 4/6 HLA matched with the pt (CI 65% vs 25%), p 5 0.2; and when CMV serostatus was reactive in both the recipient and in the non-exp unit (CI 77% vs 35%, p 5 0.1). The investigation of CB expansion is warranted in a larger study population and accrual to our study continues. Hematopoietic cell transplant in those with advanced age and/or with a higher number of co-morbid factors is a viable treatment option in this new era of reduced intensity conditioning (RIC) (McClune, et al, 2010; JCO, 2010). Based on the intensity of conditioning, RIC transplantation may require a greater degree of immune suppression to decrease the risk of graft rejection. However, greater efficacy may be counter balanced by more toxicity, particularly in older patient populations for whom these treatments are being developed. For fludarabine/TBI 200cGy conditioning with cyclosporine (CSA) and mycophenolate mofetil (MMF) graft versus host disease (GvHD) prophylaxis, CSA dosing is targeted at levels of 500-600ng/mL. In this setting, 12% of patients (median age 54) undergoing RIC procedures with these conditions experienced grade 3-5 nephrotoxicity, as defined by the NCI CTC (Diaconescu, et al, Blood, 2004). These toxicities may be even more highly accentuated in older patients. To better appreciate the prevalence and severity of adverse effects related to CSA exposure, we analyzed data from 91 patients over age 60 undergoing RIC transplant at our institution from 2001 -2010 who received CSA/MMF GvHD prophylaxis.
Double cord blood transplantation (CBT) with ex-vivo expansion aims at overcoming the delayed engraftment frequently observed after CBT. Thirty-one patients received myeloablative therapy with melphalan, fludarabine, thiotepa and ATG followed by double CBT for treatment of hematologic malignancies. One of the 2 units was expanded (exp) ex-vivo in a co-culture with either third party haploidentical family member marrow derived mesecnchyal stem cells (N 5 8) or off-the-shelf mesenchymal progenitor cells from Angioblast (N 5 23). Both CB units were matched in at least 4/6 HLA antigens with the patient, and contained a minimum of 1x10 7 TNC/ Kg per unit. The majority of patients (pts) received CBT for treatment of acute leukemia including AML / MDS (64%) and ALL (19%), and 42% were in remission at CBT. Median age was 36 years (range 2.8-62). The non-exp unit was matched with the pt in 6/6 HLA antigens in 3%, 5/6 in 26% and 4/6 in 71% of cases; the corresponding distribution for the exp unit was 6%, 29%, 64%. Engraftment was documented in 29 evaluable pts at a median of 15 (range 9 to 42) days for neutrophils and 40 (range 18 to 62) days for platelets. Day 30 chimerism showed evidence of engraftment of the non-exp unit only in 15 (52%) pts, and of both units in 13 (45%) pts, including 9 and 4 in whom the non-exp and the exp unit dominated, respectively. Chimerism was undetermined in 1 pt. Comparison of the rate of recovery in pts who had (N 5 13) and those who did not have (N 5 15) evidence of engraftment of the exp unit showed that neutrophils and platelet recovery was faster when the exp unit engrafted (median of 15 vs. 19 days for neutrophils; and 38 vs. 40 days for platelet). This difference did not reach statistical significance however. The median numbers of TNC and CD34+ cells infused/Kg were significantly higher in the engrafted exp than in the non-engrafted exp unit (p \ 0.05). Sixteen pts were diagnosed with grade II-IV aGVHD including 12 within 100 days post CBT. GVHD was severe (grade III-IV) in 5 pts. On univariate analysis, there was a trend for a higher 6 month rate of grade II-IV aGVHD when the exp unit engrafted (cumulative incidence (CI) 65% vs 49%, P 5 0.2); when the non-exp unit was only 4/6 HLA matched with the pt (CI 65% vs 25%), p 5 0.2; and when CMV serostatus was reactive in both the recipient and in the non-exp unit (CI 77% vs 35%, p 5 0.1). The investigation of CB expansion is warranted in a larger study population and accrual to our study continues. Hematopoietic cell transplant in those with advanced age and/or with a higher number of co-morbid factors is a viable treatment option in this new era of reduced intensity conditioning (RIC) (McClune, et al, 2010; JCO, 2010) . Based on the intensity of conditioning, RIC transplantation may require a greater degree of immune suppression to decrease the risk of graft rejection. However, greater efficacy may be counter balanced by more toxicity, particularly in older patient populations for whom these treatments are being developed. For fludarabine/TBI 200cGy conditioning with cyclosporine (CSA) and mycophenolate mofetil (MMF) graft versus host disease (GvHD) prophylaxis, CSA dosing is targeted at levels of 500-600ng/mL. In this setting, 12% of patients (median age 54) undergoing RIC procedures with these conditions experienced grade 3-5 nephrotoxicity, as defined by the NCI CTC (Diaconescu, et al, Blood, 2004) . These toxicities may be even more highly accentuated in older patients. To better appreciate the prevalence and severity of adverse effects related to CSA exposure, we analyzed data from 91 patients over age 60 undergoing RIC transplant at our institution from 2001 -2010 who received CSA/MMF GvHD prophylaxis.
AN INSTITUTIONAL EXPERIENCE OF ADVERSE EFFECTS IN PATIENTS OF ADVANCED AGE USING CYCLOSPORINE AND MYCOPHENOLATE MOFETIL FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN REDUCED INTENSITY CONDITIONED TRANSPLANT
Our research found numerous CSA related adverse effects including: electrolyte imbalances (100%) (hypomagnesia, hypokalemia and hyperkalemia); nephrotoxicity (88%); neurotoxicity (12%) including PRES and tremor; musculoskeletal effects in particular weakness (11%); cardiovascular impacts from CSA induced hypertension (53%) and hematologic toxicity from micro-angiopathic hemolytic anemia (1%).
The above described toxicities associated with CSA are wellknown, yet in our review of this cohort of RIC transplants the incidence of CSA related adverse events was pronounced. This level of adverse events requires more aggressive monitoring and management which leads to increased resource utilization of medical personnel and dollars, and may have a negative effect on patient outcomes. In practice, we should continue to explore ways to optimize patient care while controlling expense and resource utilization, and obtain a greater understanding of the role that age and co-morbid factors have on the transplant course given the expanding role of RIC. To that end, we are currently comparing the rates of CSA-induced complications in this cohort to a group of comparable patients undergoing myeloablative transplant.
L-LEUCYL-L-LEUCINE METHYL ESTER (LLME) TREATED NON-MYELOA-BLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Wagner, J.L., Grosso, D.A., Brunner, J., Carabasi, M.A., Filicko-O'Hara, J.E., Mookerjee, B., Flomenberg, N. Thomas Jefferson University, Philadelphia, PA GVHD remains an obstacle for allogeneic HSCT. While T cell depletion of donor grafts results in much lower incidences of GVHD, rejection and poor immune recovery are often associated with this approach. To address these issues, we developed a transplant approach using LLME to test the hypothesis that the selected depletion of T cells containing cytotoxic effector granules would result in less significant GVHD while at the same time preserving GVT effects and infectious immunity. LLME preferentially kills cytotoxic effector granule bearing lymphocytes including most NK and CD8 T cells with relative sparing of CD4 T cells. Fourteen patients, with a median age of 57 years with high risk disease were transplanted from related or unrelated donors after a conditioning regimen of flu/cyclo/ara-C. Prior to the infusion of the donor inoculum, we performed CD34 selection using the IsolexÒ system to separate the graft into CD34+ and CD34-fractions. The CD34-fraction was then treated with LLME to selectively deplete the cytotoxic effector granule containing subsets, thus avoiding stem cell exposure to LLME. Patients received the CD34 selected stem cell product (median CD34 dose 4.13 x 10 6 / kg). This HSC product contained 5 x 10 4 untreated CD3 cells/kg in the initial 6 patients treated, but due to significant GVHD, the final 8 patients received 2.5 x 10 4 untreated CD3 cells/kg. One day later, the LLME treated CD34-fraction (median CD3 dose 8.74 x10 6 /kg) was infused. One patient died shortly after the stem cell infusion from infectious complications. All 13 evaluable patients engrafted WBC by day 14. Two patients experienced late rejection. One of these patients is still alive 3 years later with evidence of recurrent disease and the other patient eventually died of relapsed disease. Of the remaining 11 patients, 3 patients developed grade III-IV GVHD and 1 patient developed cGVHD. All 4 of these patients died of GVHD related causes. Three patients died of complications from relapsed disease and 1 additional patient died of infectious complications. Four patients are alive at a minimum of 3 years post transplant. Two of these patients have relapsed disease, 1 patient is disease free with 100% donor chimerism and one patient is disease free with a persistence of 5% host cells. This study shows that LLME can be used to treat lymphocytes without affecting initial engraftment, but relapse and GVHD remain significant barriers in this high risk population.
MELPHALAN AND TOTAL-BODY IRRADIATION (MEL-TBI) IS AN EFFEC-TIVE CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANS-PLANTATION (ALLO-SCT) IN PATIENTS WITH VERY POOR-RISK REFRACTORY HEMATOLOGIC MALIGNANCIES
Akpek, G., Marangoz, D., Ilyas, C., Akbulut, V., Bhatnagar, B., Ruehle, K., Badros, A.Z., Yanovich, S., Rapoport, A.P. University of Maryland Medical Center, Baltimore, MD
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